<?xml version="1.0" encoding="UTF-8"?>
<p>RNA interference (RNAi) represents a reliable approach to identify genes important in diseases such as acute myeloid leukemia, epithelial ovarian cancer, and schistosomiasis (
 <xref rid="B5" ref-type="bibr">5</xref>
 <xref ref-type="bibr" rid="B6">–</xref>
 <xref rid="B7" ref-type="bibr">7</xref>). Genomewide RNAi screening has been used to identify host genes involved in the replication of the moderately pathogenic influenza H1N1 virus (
 <xref rid="B8" ref-type="bibr">8</xref>
 <xref ref-type="bibr" rid="B9">–</xref>
 <xref rid="B15" ref-type="bibr">15</xref>). Data mining using public databases such as the DrugBank database and the Therapeutic Target Database (TTD) has been increasingly used to identify candidate drugs that could potentially interact with known validated target genes (
 <xref rid="B16" ref-type="bibr">16</xref>, 
 <xref rid="B17" ref-type="bibr">17</xref>). We combined RNAi screening and DrugBank and TTD target gene searches to develop an effective method for identifying repurposable drugs.
</p>
